Key result
YWHAE-NUTM2A/B translocated high-grade endometrial stromal sarcoma commonly expresses CD56 (100% of cases) and CD99 (85% of cases), which may assist in diagnosis.
Observational (n=20)
YWHAE-NUTM2A/B translocated high-grade endometrial stromal sarcomas commonly express CD56 and CD99, which can assist in diagnosis but also requires careful differentiation from other small round cell tumors.
Answers are grounded in this paper and cite their sources.
May aid diagnosis of this rare sarcoma; leaves open validation in larger series.
YWHAE-NUTM2A/B translocated high-grade endometrial stromal sarcoma is an uncommon and clinically aggressive uterine mesenchymal neoplasm which is sometimes associated with a low-grade fibromyxoid component. Although the diagnosis is confirmed using molecular techniques, it is possible to make the diagnosis based on the characteristic morphology and the immunophenotype; the latter typically includes diffuse positive staining of the high-grade component with cyclin D1 and CD117 and negative staining with CD10 and hormone receptors. Especially in a small biopsy specimen, in cases without a low-grade component or when presenting with extrauterine disease, the differential diagnosis may be wide and potentially include "small round cell tumors" such as a high-grade neuroendocrine carcinoma and a tumor in the Ewing family. In this study, we report consistent CD56 and CD99 immunoreactivity in YWHAE-NUTM2A/B translocated high-grade endometrial stromal sarcoma. We stained 20 of these neoplasms (10 molecularly confirmed and 10 where diagnosis was based on the morphology and immunophenotype) with CD56 and CD99; in one case, CD56 staining was not performed. Nineteen of 19 (100%) and 17 of 20 (85%) were positive with CD56 and CD99, respectively. Staining was usually diffuse with membranous and cytoplasmic immunoreactivity. Pathologists should be aware that YWHAE-NUTM2A/B translocated high-grade endometrial stromal sarcoma is commonly positive with CD56 and CD99; as well as potentially assisting in diagnosis, positivity with these markers may also result in consideration of other neoplasms in the differential diagnosis.
No takes yet. Share an insight, caveat, or question.
McCluggage et al. (2018) conducted an observational in YWHAE-NUTM2A/B translocated high-grade endometrial stromal sarcoma (n=20). CD56 and CD99 staining was evaluated on CD56 and CD99 immunoreactivity. YWHAE-NUTM2A/B translocated high-grade endometrial stromal sarcoma commonly expresses CD56 (100% of cases) and CD99 (85% of cases), which may assist in diagnosis.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: